Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Surviva…

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall ...
ascopubs.org

The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors.

This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full text component.
Healio

Immunotherapy combination may improve outcomes in unresectable liver cancer

Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are ...

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain ...

Merck's TroFuse-005 Trial Evaluating Sac-TMT Met Primary Endpoints of OS and PFS in Certain Patients With Advanced or Recurrent Endometrial Cancer ...
Morningstar

Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study

HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, ...
Cancer Therapy Advisor

Chiauranib Extends Progression-Free Survival in Platinum-Resistant Ovarian Cancer

Adding chiauranib to weekly paclitaxel improves PFS, but not OS, in patients with platinum-resistant or refractory ovarian cancer.
Pharmabiz

Merck announces TroFuse-005 trial of sacituzumab tirumotecan meets primary endpoints of OS and PFS in certain patients with advanced or recurrent endometrial cancer

Merck announces TroFuse-005 trial of sacituzumab tirumotecan meets primary endpoints of OS and PFS in certain patients with advanced or recurrent endometrial cancer: Rahway, New J ...